According to recent foreign media reports, Quantum Surgical has completed its acquisition of NeuWave Medical, a Johnson & Johnson subsidiary. Financial details of the transaction have not yet been disclosed. Furthermore, it is worth noting that the two companies will become subsidiaries of the newly formed holding company, Precision IO Group Inc.According to Johnson & Johnson, NeuWave Medical is a leading provider of interventional oncology solutions in the United States, and was acquired by Johnson & Johnson in 2016. According to data from PharmNet Medical Devices, NeuWave currently has 14 products on the market in the United States , including the Certus air-cooled microwave ablation device and disposable microwave ablation needles, primarily used for image-guided tumor ablation therapy.

In 2020, NeuWave Medical officially entered China, and currently has two products on the market in China : a microwave ablation therapy device and a disposable microwave ablation puncture needle.

In 2025, Johnson & Johnson announced it would cease operations of NeuWave Medical, and then formally announced its decision to sell the business in September of that year. Now, with the completion of the acquisition, Quantum Surgical will officially take over NeuWave Medical.

Founded in 2017, Quantum Surgical has focused on developing robot-assisted surgical systems for minimally invasive cancer treatment . According to data from PharmNet Medical Devices, its core product, the Epione robotic platform, is already available in China. As its new owner, Quantum Surgical will acquire NeuWave's microwave ablation platform, a technology reportedly used in percutaneous ablation surgery that utilizes electromagnetic waves to heat and destroy large tumors.

In a joint statement regarding the acquisition, the two companies stated that NeuWave Medica's technology is currently used by 70% of the top cancer centers in the United States, and that this technology complements Quantum Surgical's Epione robotic platform, which focuses on early-stage cancer treatment and can provide precise guidance for doctors when performing percutaneous tumor ablation.

It is worth noting that Johnson & Johnson has carried out a series of strategic adjustments in recent years. In addition to selling NeuWave Medical, Johnson & Johnson is also evaluating the divestiture of its orthopedic business DePuy Synthes this year . This business may be sold directly for more than $20 billion and will not be spun off and listed separately.

Following the split, Johnson & Johnson will concentrate its resources on developing six key growth areas : oncology, immunology, neuroscience, cardiovascular, surgery, and vision-related businesses.

In addition, Johnson & Johnson officially announced at the end of 2025 that it would implement an organizational restructuring, changing the way its business units operate . Starting from January 1, 2026, it will shift from a regional model to a business unit-led operating model globally, and has made a series of adjustments to its departments and leadership, moving to a new business unit-led structure , aiming to improve organizational agility, deepen professional focus and accelerate market response.

https://news.yaozh.com/archive/47317.html